Everybody has their reasons for embracing, or shunning, an emerging market strategy. But if you want to know what ‘the world’s leading drug maker’ is thinking about emerging markets, and their reasons for thinking it, you’ll check out this very brief bulletin today in FinancierWorldwide featuring Jean-Michel Halfon, who runs Pfizer’s emerging market unit.
The news item pinpoints Pfizer’s first emerging market targets and says that double digit growth opportunities there, versus ‘lagging revenues in developed economies, such as the US and Europe’ are driving the strategy among big players like Pfizer.
GHS and Regulatory Labeling Challenges in the New Era 
